{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:hse:00424:b:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahse%3A00424%3Ab%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002319,
    "timestamp_received": "2026-10-16T23:59:38.542223+00:00Z",
    "timestamp_returned": "2026-10-16T23:59:38.544542+00:00Z",
    "trace_id": "1f188bc5-7f4a-4852-99a9-1136c5f7eaff"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:hse:00424:b:0",
      "type": "Statement",
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved obinutuzumab in combination with bendamustine for reimbursement as a treatment option for the treatment of patients with previously untreated advanced follicular lymphoma. The treatment regimen describes eligibility criteria separately for use within the first and second line of treatment. In a first line setting, patients must have previously untreated, CD20-positive follicular lymphoma (grade 1 to 3a) with advanced disease (stage III, stage IV, or stage II with bulk disease [tumor >= 7 cm in the greatest dimension]), ECOG status 0-2, and adequate hematological, renal, and liver status. In the second line setting, patients must have CD20-positive indolent non-Hodgkin lymphoma refractory to rituximab, ECOG 0-2 (ECOG 3 at the discretion of the treating clinician), and adequate hematological, renal, and liver status.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2026-08-02:0",
          "type": "Contribution",
          "description": "Initial curation of into moalmanac-db",
          "date": "2026-08-02",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:hse:2019-05-01:0",
          "type": "Contribution",
          "description": "Indication approved for reimbursement.",
          "date": "2019-05-01",
          "contributor": {
            "id": "agent:org:hse",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Service Executive",
            "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse:00424",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Obinutuzumab and Bendamustine Therapy - 28 day cycle. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Obinutuzumab and Bendamustine Therapy - 28 day cycle, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2017-10-10",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2026-03-06",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:929",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C3209",
          "conceptType": "Disease",
          "name": "Follicular Lymphoma",
          "mappings": [
            {
              "relation": "exactMatch",
              "coding": {
                "id": "coding:oncotree:FL",
                "code": "FL",
                "name": "Follicular Lymphoma",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Follicular+Lymphoma+%28FL%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": false,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C3209",
            "code": "C3209",
            "name": "Follicular Lymphoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3209"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "txgrp:202",
          "membershipOperator": "AND",
          "therapies": [
            {
              "id": "tx:ncit:C73261",
              "conceptType": "Therapy",
              "name": "Bendamustine",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:134547",
                    "code": "134547",
                    "name": "bendamustine",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=134547"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:19015523",
                    "code": "19015523",
                    "name": "bendamustine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/19015523"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Alkylating chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C73261",
                "code": "C73261",
                "name": "Bendamustine",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C73261"
                ]
              }
            },
            {
              "id": "tx:ncit:C70741",
              "conceptType": "Therapy",
              "name": "Obinutuzumab",
              "mappings": [
                {
                  "relation": "exactMatch",
                  "coding": {
                    "id": "coding:rxcui:974779",
                    "code": "974779",
                    "name": "obinutuzumab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=974779"
                    ]
                  }
                },
                {
                  "relation": "exactMatch",
                  "coding": {
                    "id": "coding:omop:44507676",
                    "code": "44507676",
                    "name": "obinutuzumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/44507676"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "CD20 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Targeted therapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C70741",
                "code": "C70741",
                "name": "Obinutuzumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C70741"
                ]
              }
            }
          ]
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:54",
                "present": true,
                "subject": {
                  "id": "bmkr:54",
                  "type": "CategoricalVariant",
                  "name": "CD20 +",
                  "constraints": [],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Protein expression"
                    },
                    {
                      "name": "marker",
                      "value": "CD20"
                    },
                    {
                      "name": "unit",
                      "value": "status"
                    },
                    {
                      "name": "equality",
                      "value": "="
                    },
                    {
                      "name": "value",
                      "value": "Positive"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:hse:00424:b",
            "type": "Indication",
            "description": "Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2026-08-02:0",
                "type": "Contribution",
                "description": "Initial curation of into moalmanac-db",
                "date": "2026-08-02",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:hse:2019-05-01:0",
                "type": "Contribution",
                "description": "Indication approved for reimbursement.",
                "date": "2019-05-01",
                "contributor": {
                  "id": "agent:org:hse",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "Health Service Executive",
                  "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:hse:00424",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Obinutuzumab and Bendamustine Therapy - 28 day cycle. NCCP National SACT Regimen. HSE.",
                "title": null,
                "aliases": [],
                "description": "Obinutuzumab and Bendamustine Therapy - 28 day cycle, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf",
                "urls": [
                  "https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:hse",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "Health Service Executive",
                      "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": null,
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": null,
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2017-10-10",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2026-03-06",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              },
              {
                "name": "reimbursement_scheme",
                "value": "ODMS",
                "description": "Current scheme used to reimburse indication."
              },
              {
                "name": "reimbursement_comment",
                "value": null,
                "description": "More details about the current reimbursement scheme(s)."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}